Greinix, Hildegard T.
Attarbaschi, Andishe
Girschikofsky, Michael
Greil, Richard
Holter, Wolfgang
Neumeister, Peter
Peters, Christina
Petzer, Andreas
Rudzki, Jakob
Schlenke, Peter
Schmitt, Clemens A.
Schwinger, Wolfgang
Wolf, Dominik
Worel, Nina
Jaeger, Ulrich
Funding for this research was provided by:
Medical University of Graz
Article History
Received: 27 January 2020
Accepted: 28 January 2020
First Online: 20 February 2020
Conflict of interest
: H.T. Greinix received honoraria for presentations at scientific meetings and consultancy from Celgene, Novartis and Janssen. U. Jaeger declares honoraria and research grants from Novartis, Gilead, Celgene, Miltenyi and Janssen. A. Attarbaschi is a consultant for Jazz Pharmaceuticals and Novartis; travel and accommodation expenses were covered by Jazz Pharmaceuticals, Amgen and Pfizer. M. Girschikofsky is a consultant for Celgene. C. Peters works at the speakers bureau and advisory board for Novartis and Amgen. A. Petzer received honoraria from Novartis, Gilead, Celgene and Janssen-Cilag; travel support from Gilead and Janssen-Cilag. J. Rudzki works at the speakers bureau for BMS/Celgene, Roche, MSD, AstraZeneca, Amgen, Gilead and Novartis; is on the advisory board for Roche, MSD, AstraZeneca, Amgen, Gilead, Novartis and BMS/Celgene. N. Worel works at the speakers bureau for Novartis and Gilead; gets travel support from Novartis and Celgene; is on the advisory board for Novartis and Celgene. R. Greil, W. Holter, P. Neumeister, P. Schlenke, C.A. Schmitt, W. Schwinger and D. Wolf declare that they have no competing interests.